ImmuCell (ICCC) vs Intellia Therapeutics (NTLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImmuCell (ICCC) has outperformed Intellia Therapeutics (NTLA) over the past year, gaining 50.2% versus a loss of 42.7%. Over five years, ICCC leads with a +4.4% price change compared with -91.0% for NTLA. Intellia Therapeutics is the larger company by market cap ($1.70 billion vs $89.5 million), about 19.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICCC | NTLA |
|---|---|---|
| Share price | $9.85 | $12.12 |
| Market cap | $89.46M | $1.70B |
| 1-day change | +1.65% | +3.50% |
| YTD return | +57.56% | +30.26% |
| 1-year return | +50.23% | -42.71% |
| 5-year return | +4.42% | -91.03% |
| P/E ratio (TTM) | 140.71 | — |
| EPS (TTM) | $0.07 | $-3.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.10 | $28.25 |
| 52-week low | $4.52 | $7.95 |
| Distance from 52-week high | -18.60% | -57.10% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +90.67% |
| Average volume | 22.88K | 4.16M |
| Shares outstanding | 9.08M | 140.13M |
| Employees | — | 377 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Intellia Therapeutics is about 19.0 times larger than ImmuCell by market value ($1.70B vs $89.46M).
- ICCC has outperformed NTLA by 92.9 percentage points over the past year.
About Intellia Therapeutics
NTLA stock →Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 377 employees
ICCC vs NTLA FAQ
Which is bigger, ImmuCell or Intellia Therapeutics?
Intellia Therapeutics (NTLA) is larger, with a market capitalization of $1.70B compared with $89.46M for ImmuCell (ICCC).
Which stock has performed better over the past year, ICCC or NTLA?
ICCC returned +50.23% over the past 12 months, compared with -42.71% for NTLA (price return, excluding dividends). Past performance does not predict future results.
Are ImmuCell and Intellia Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.